Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H22FN3O3 |
Molecular Weight | 359.3947 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCN(CC1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O
InChI
InChIKey=SPFYMRJSYKOXGV-UHFFFAOYSA-N
InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
Molecular Formula | C19H22FN3O3 |
Molecular Weight | 359.3947 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM062413.pdfCurator's Comment: description was created based on several sources, including, http://file.scirp.org/pdf/OJVM_2016022615035704.pdf, https://actualidadveterinaria.files.wordpress.com/2011/10/fluoroquinolones-then-and-now.pdf
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM062413.pdf
Curator's Comment: description was created based on several sources, including, http://file.scirp.org/pdf/OJVM_2016022615035704.pdf, https://actualidadveterinaria.files.wordpress.com/2011/10/fluoroquinolones-then-and-now.pdf
Enrofloxacin was developed by Bayer for the treatment of broad spectrum of bacterial infections in animals (cats and dogs). The drug exerts its action by inhibiting DNA Topoisomerase II (Gyrase) and DNA Topoisomerase IV (Topo IV), two major bacterial topoisomerase. Enrofloxacin was shown to be metabolized to ciprofloxacin and may cross the blood brain barrier in the animals.
Originator
Sources: http://www.baytril.com/en/home/history/
Curator's Comment: Enrofloxacin was synthesized by Bayer researchers Grohe and Peterson in 1980 # Bayer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 Sources: http://file.scirp.org/pdf/OJVM_2016022615035704.pdf |
|||
Target ID: CHEMBL2363076 Sources: http://file.scirp.org/pdf/OJVM_2016022615035704.pdf |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BAYTRIL Approved UseBaytril Antibacterial Tablets and Injectable Solution are indicated for the management of diseases in dogs and cats associated with bacteria susceptible to enrofloxacin. Launch Date1.14048002E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. | 2000 Dec |
|
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. | 2000 Oct |
|
Interaction of fluoroquinolones and certain ionophores in broilers: effect on blood levels and hepatic cytochrome p450 monooxygenase activity. | 2001 |
|
Antibacterial drugs prescribed for dogs and cats in Sweden and Norway 1990-1998. | 2001 |
|
Characterisation of some Ornithobacterium rhinotracheale strains and examination of their transmission via eggs. | 2001 |
|
Antimicrobial susceptibility of intestinal bacteria from Swiss poultry flocks before the ban of antimicrobial growth promoters. | 2001 Apr |
|
Hypoadrenocorticism in a cat. | 2001 Apr |
|
Diagnosis and treatment of conjunctivitis in house finches associated with mycoplasmosis in Minnesota. | 2001 Apr |
|
Determination of fluoroquinolones in serum using an on-line clean-up column coupled to high-performance immunoaffinity-reversed-phase liquid chromatography. | 2001 Apr 15 |
|
Effects of the matrix and sample preparation on the determination of fluoroquinolone residues in animal tissues. | 2001 Apr 20 |
|
Monitoring Mycoplasma gallisepticum and Mycoplasma synoviae infection in breeder chickens after treatment with enrofloxacin. | 2001 Apr-Jun |
|
Determination of residues of enrofloxacin and its metabolite ciprofloxacin in biological materials by capillary electrophoresis. | 2001 Aug 5 |
|
Organic acid profiles in feces of pigs with pathogenic or non-pathogenic diarrhea. | 2001 Dec |
|
Epidemiological studies of human and animal Salmonella typhimurium DT104 and DT104b isolates in Ireland. | 2001 Feb |
|
Effects of enrofloxacin and magnesium deficiency on matrix metabolism in equine articular cartilage. | 2001 Feb |
|
Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). | 2001 Feb 1 |
|
Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats. | 2001 Jan |
|
Effect of enrofloxacin-Na against pathogens related to the respiratory and alimentary diseases in suckling and weanling piglets. | 2001 Jan |
|
Non-bioequivalence of various trademarks of enrofloxacin and Baytril in cows. | 2001 Jul |
|
Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates. | 2001 Jul 3 |
|
The use of antibiotics critical to human medicine in food-producing animals in Taiwan. | 2001 Jun |
|
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998. | 2001 Mar |
|
Development of an indirect competitive ELISA for ciprofloxacin residues in food animal edible tissues. | 2001 Mar |
|
In vitro evidence for effects of magnesium supplementation on quinolone-treated horse and dog chondrocytes. | 2001 Mar |
|
Addressing the use of fluoroquinolone antibiotics in agriculture. | 2001 Mar |
|
Characterization of high-level fluoroquinolone resistance in Escherichia coli O78:K80 isolated from turkeys. | 2001 Mar |
|
Effects of an experimental infection with Actinobacillus pleuropneumoniae on the interferon-alpha and interleukin-6 producing capacity of porcine peripheral blood mononuclear cells stimulated with bacteria, virus or plasmid DNA. | 2001 Mar 20 |
|
Serogroups and antimicrobial susceptibility among Escherichia coli isolated from farmed mink (Mustela vison Schreiber) in Denmark. | 2001 Mar 20 |
|
Inhibition tests for detection and presumptive identification of tetracyclines, beta-lactam antibiotics and quinolones in poultry meat. | 2001 May |
|
Effects of enrofloxacin and ciprofloxacin hydrochloride on canine and equine chondrocytes in culture. | 2001 May |
|
In vitro susceptibility to 15 antibiotics of vibrios isolated from penaeid shrimps in Northwestern Mexico. | 2001 May |
|
Absorption spectra of the 4f electron transitions of the praseodymium complex with 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(4-ethyl-1-piperazinyl) -4-oxo-3-quinoline carboxylic acid hydrochloride and its analytical application. | 2001 Sep |
|
Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs. | 2001 Sep |
|
Antimicrobial susceptibility of udder pathogens isolated from dairy herds in the west littoral region of Uruguay. | 2002 |
|
Biofilm bacteria: formation and comparative susceptibility to antibiotics. | 2002 Apr |
|
Questions study on Escherichia coli susceptibility. | 2002 Apr 15 |
|
Idiosyncratic reaction to enrofloxacin in cats. | 2002 Apr 27 |
|
In vitro development of resistance to enrofloxacin, erythromycin, tylosin, tiamulin and oxytetracycline in Mycoplasma gallisepticum, Mycoplasma iowae and Mycoplasma synoviae. | 2002 Aug 2 |
|
Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. | 2002 Feb |
|
Using nonaqueous capillary electrophoresis to analyze several quinolones in pig kidney samples. | 2002 Feb |
|
Elimination of mycoplasma from leukemia-lymphoma cell lines using antibiotics. | 2002 Feb |
|
Monoclonal-based enzyme-linked immunosorbent assay and immunochromatographic assay for enrofloxacin in biological matrices. | 2002 Jan |
|
Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae. | 2002 Jan |
|
Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine. | 2002 Jan |
|
Spectrophotometric determination of ciprofloxacin, enrofloxacin and pefloxacin through charge transfer complex formation. | 2002 Jan 1 |
|
Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. | 2002 Jan 15 |
|
Pathotypes of avian Escherichia coli as related to tsh-, pap-, pil-, and iuc-DNA sequences, and antibiotic sensitivity of isolates from internal tissues and the cloacae of broilers. | 2002 Jan-Mar |
|
Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. | 2002 Jul |
|
Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Escherichia coli, and Salmonella choleraesuis recovered from Taiwanese swine. | 2002 Mar |
|
Bayer seeks veterinary, industry backing before Baytril hearing. | 2002 May 15 |
Patents
Sample Use Guides
The dose range of Baytril (Enrofloxacin) Antibacterial Tablets in dogs and cats is 5 to 20 mg/kg (2.27 to 9.07 mg/lb) of body weight, either as a single dose or divided into two (2) equal daily doses administered at twelve (12) hour intervals. The dose of Baytril Injectable Solution for dogs is 2.5 mg/kg (1.13 mg/lb) as a single injection. The injectable dose should be followed by oral tablet treatment in 12 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/12801456
The minimum inhibitory concentration (MIC) enrofloxacin against 24 Sicilian isolates of Mycoplasma agalactiae, the causative organism of contagious agalactia were determined in vitro by a broth dilution method. Enrofloxacin was effective antimicrobial in vitro with a range of MIC values from 0.125 to 0.500 microg/ml and an MIC(50) of 0.203 and MIC(90) of 0.365 microg/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:12:38 UTC 2023
by
admin
on
Wed Jul 05 23:12:38 UTC 2023
|
Record UNII |
3DX3XEK1BN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01MA90
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
||
|
CFR |
21 CFR 556.226
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
||
|
CFR |
21 CFR 520.812
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
||
|
CFR |
21 CFR 524.802
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
||
|
CFR |
21 CFR 522.812
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Enrofloxacin
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
71188
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
3DX3XEK1BN
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
24192
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | RxNorm | ||
|
300000023676
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
C72660
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
758616
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
5963
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
Z-54
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
6952
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
DTXSID1045619
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
93106-60-6
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
CHEMBL15511
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
DB11404
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
C052904
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
M4916
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | Merck Index | ||
|
3DX3XEK1BN
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
1235900
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY | |||
|
35720
Created by
admin on Wed Jul 05 23:12:38 UTC 2023 , Edited by admin on Wed Jul 05 23:12:38 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |